Provider review
Roen Rx review
Prices the insured and uninsured paths together, and the small figure is a copay.
A copay headline sits beside a four-figure cash price for the same branded drugs. The gap between them is the most important fact about branded pricing.
Reviewed by Lena OrtizMetabolic Health Editor
Price updated August 2026
How we’re funded. Some links here are affiliate links: start care through one and we may earn a commission, at no extra cost to you. Affiliate partners are listed first on our rankings — what we write about a provider is the same either way, and unflattering findings about one that pays us stay in. Full disclosure.
Price as published
Roen Rx
Branded as low as $25/mo with insurance; four figures without it
FDA warning letter · Roen Rx · June 2026 · addressed to Roen Health, Inc. dba RoenRx. Details in our review.
- Vs median
- Not comparable — the figure is an insurance copay outcome rather than a price the provider sets, so it depends on a plan we cannot read
- Market
- $59–$1300/mo across 242 of 373
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
In one paragraph
The verdict
Both paths are priced on one page, which is more than most sellers here manage: the branded GLP-1s quoted at an insurance copay, and the cash price for the same medicines directly beside it. The distance between those two numbers is the single most important fact about branded GLP-1 pricing, and most providers leave a reader to discover it only after signing up. Read the small figure correctly, though. It is a copay outcome depending entirely on a plan this provider neither sets nor sees, so it is not a rate anybody can budget from without establishing their own coverage first. No dose sits behind any figure. One thing about the evidence is worth checking: the site states that medications containing semaglutide have shown a particular average weight loss, and attaches that range to compounded products — the trials producing it tested the branded medicines. And one piece of context rather than criticism: this brand runs on a shared telehealth platform, and two others reviewed here run on the same one with the same prices. White-labeling is ordinary in this industry and implies nothing about the standard of care. It is worth knowing for one narrow reason — if you check these three against each other and find the same numbers, that is not independent corroboration.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
Who it suits, and who it does not
A good fit if
- You want both the insured and uninsured paths priced on one page.
- You want branded GLP-1s rather than compounded preparations alone.
- You want billing and membership terms answered directly in the FAQ.
Look elsewhere if
- You are pricing a dose. No milligram figure is published behind anything.
- You are anchoring on the headline. It is an insurance copay outcome, not a price.
- You check where outcome figures come from. Its trial range is attached to compounded products.
What it actually costs
Price as published
Its pricing, its FAQ and 27 verbatim sentences are IDENTICAL to two other brands reviewed here — Zealthy and FitRx — down to the same $25-with-insurance headline, the same four-figure cash number for the branded drugs, and the same page structure down to the layout of the FAQ · each of the three carries its own separate copyright and presents as an independent company · so a reader who compares these three is comparing one platform three times, and any sense of having checked the market is an illusion · the figures themselves: branded GLP-1s advertised "as low as $25/month" with insurance against roughly $1,349 without · the shared copy includes "medications with the active ingredient semaglutide have shown 15-20% average weight loss", a trial figure attached to compounded products across all three sites
- Vs median
- Not comparable — the figure is an insurance copay outcome rather than a price the provider sets, so it depends on a plan we cannot read
- Market
- $59–$1300/mo is the full published spread in our ranking
- Structure
- Standard plan, self-directed low dose
No low-dose product of its own. Starting low means asking for a smaller amount inside a standard plan, at the standard plan's price.
152 of the 373 programs we track price a small dose this way. One of three brands here sharing identical pricing, FAQ and 27 verbatim sentences. Its headline is an insurance COPAY outcome rather than a price, so nothing is readable as a rate a reader can plan on. No low-dose product is offered.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
What is included
- Consult
- Included in the price
- Dietitian
- Not included
- Labs
- Not required
- Pricing
- Varies by dose, plan or tier
- Price last updated
- August 2026
What it does well
- Both the insured and uninsured paths are priced on the same page.
- Carries the branded GLP-1s rather than compounded preparations alone.
- The FAQ answers billing and membership questions directly rather than deflecting.
Pharmacy, labs and oversight
Roen Rx dispenses through a Not named facility. No bloodwork is required before you start. A clinician review is included in the price.
Transparency check
1 of 4 published openly
What Roen Rx publishes about itself, read from its own pages when we verified them — not estimated, and not a score.
- Pharmacy named and regulatedNo pharmacy is identified anywhere we could find on its own pages.
- Published
- A price you can read before intakeThe figure appears only after an intake quiz, so it cannot be compared before signing up.
- Not published
- What a higher dose costsPriced by dose, plan or tier, and the higher rungs are not published — the advertised figure does not tell you what a larger dose costs.
- Not published
- FDA warning letter on fileOne is on file. The disclosure and the FDA's own database are directly below.
- On file
FDA warning letter
The U.S. Food and Drug Administration issued a warning letter to Roen Rx in June 2026. It is addressed to Roen Health, Inc. dba RoenRx — search that name, not ours, to find it. We are not summarizing what it says — read it at the source. This does not change how Roen Rx is listed here or whether we are paid for a click to it, and we would rather you knew both of those things at once.
How the program works
The useful thing here is that both paths appear together: the branded GLP-1s are quoted at an insurance copay and the cash price for the same drugs sits on the same page, and the distance between those two numbers is the single most important fact about branded pricing. Read the small one correctly, though — it is a copay outcome that depends entirely on a plan this provider does not control, not a rate it sets, and putting it in the headline invites a reader to budget around a figure that may not apply to them. No dose sits behind any figure. One further caution about the evidence: the site states that medications with the active ingredient semaglutide have shown a specific average weight loss, and attaches that range to compounded products — those trials tested the branded medicines. Context rather than criticism: this brand runs on a shared telehealth platform, and two others reviewed here run on the same one with the same prices and much of the same copy. White-labeling is ordinary in this industry and says nothing about the quality of care. It is worth knowing only because agreement between those three is not corroboration.
The honest cons
No dose is published behind any figure, so what a low dose costs is unstated.
- The headline figure is an insurance copay outcome, not a price the provider sets.
- Its shared copy attaches a clinical-trial weight-loss range to compounded products.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
How it compares
Roen Rx is one of 373 low-dose GLP-1 programs we track, and 242 of them publish a monthly rate you can read before signing up. The ranking lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.
Where this sits
#220 of 373
Ordered with the companies that pay us first, and Roen Rx is not one of them. A disclosed partition, not a score.
Compare all 373 providers →Read this before you buy
Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
The closest alternative
RxSpan MD
From $194/mo
- Vs median
- $25/mo above the $169 median
- Market
- $59–$1300/mo across 242 of 373
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
Read the RxSpan MD review →Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.